BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will host a virtual key opinion leader (KOL) event on Monday, October 20, 2025 at 8:00 AM ET featuring company leadership and Kyriakos Papadopoulos, MD (Co-Director of Clinical Research at START, San Antonio), who will discuss the unmet need and current treatment lan ...

Summary of Sensei Biotherapeutics (SNSE) FY Conference - September 05, 2025 Company Overview - **Company**: Sensei Biotherapeutics - **Industry**: Biotechnology - **Focus**: Developing conditionally active antibodies for cancer using the Tumor Microenvironment Activated Biologics (TMAb) platform [1] Core Points and Arguments 1. **Defining Year**: 2025 is highlighted as a pivotal year for Sensei Biotherapeutics, transitioning from early promise to more mature efficacy signals, with phase one to dose expansion results expected at the ESMO Congress in October [2] 2. **Lead Program - SylvesterTOG**: - Positioned as the first credible VISTA-targeted therapy, aiming to address issues that previously hindered VISTA-focused antibodies [2] - Designed to selectively bind in the acidic tumor microenvironment, minimizing toxicity and improving pharmacokinetics [3] 3. **Market Opportunity**: - The PD-L1 therapy market is valued at $50 billion, with VISTA expressed in most solid tumors, indicating a significant potential for SylvesterTOG [3] - The approach aims to open a new checkpoint pathway that could rival PD-L1 therapies [3] 4. **Collaboration with Regeneron**: Evaluating SylvesterTOG in combination with Regeneron's PD-1 inhibitor, Libtayo, across various tumors, showcasing the innovative approach and recognition of VISTA's role in immunotherapy resistance [4] 5. **Safety and Efficacy**: - SylvesterTOG has shown a favorable safety profile with no dose-limiting toxicities and manageable cytokine release events, contrasting with earlier VISTA programs that faced severe issues [5] - The trial focused on "hot tumors," with historical response rates for PD-1 rechallenge being in the single digits, yet SylvesterTOG demonstrated remarkable activity [6][7] 6. **Durability of Response**: - Emphasis on the importance of durable responses in immunotherapy, with several patients showing long-term benefits from SylvesterTOG [8][9] - Full phase one to dose expansion data, including six-month progression-free survival (PFS) metrics, will be presented at ESMO [10] 7. **Safety Profile in Expansion Cohort**: Most adverse events were grade one or two, with low-grade cytokine release, indicating a well-tolerated treatment [11] 8. **Future Plans**: - Plans to initiate phase two studies in 2026, with multiple trials aligned with unmet medical needs and commercial potential [11] - Financially positioned with a cash runway into 2026 to support upcoming milestones [12] Other Important Content - **Recognition at ESMO**: The data will be featured in a mini oral session at ESMO, marking a significant recognition of the work being done on VISTA as a therapeutic target [10] - **Investor Opportunity**: Sensei Biotherapeutics presents a unique investment opportunity in the first successful unlocking of VISTA's myeloid biology, which could reshape the immuno-oncology landscape [12]

Company Overview - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target immunosuppressive signals in the tumor microenvironment [3] - The lead product candidate is solnerstotug, an antibody designed to block the VISTA checkpoint selectively in low pH tumor environments [3] Upcoming Events - John Celebi, President and CEO of Sensei Biotherapeutics, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [1] - An on-demand corporate presentation will be available on September 5, 2025, at 7:00 a.m. ET, with a replay accessible for approximately 90 days [2]

Core Insights - Sensei Biotherapeutics reported a Q2 2025 loss per share of $(3.91), which was better than the expected $(5.60) loss, indicating improved financial performance [1][2] - The company achieved a net loss of $4.9 million in Q2 2025, down from a net loss of $7.1 million in Q2 2024, reflecting effective cost management [1][2] - Sensei Biotherapeutics remains in the early stages of development with no revenue reported, consistent with its status as a clinical-stage biotech company [1][8] Financial Performance - Q2 2025 EPS was $(3.91), compared to $(5.60) estimated and $(5.69) in Q2 2024, showing a year-over-year improvement of 31.3% [2] - Research and Development expenses decreased to $2.5 million in Q2 2025 from $4.6 million in Q2 2024, a reduction of 46.0% [2][7] - General and Administrative expenses fell to $2.7 million in Q2 2025 from $3.2 million in Q2 2024, a decrease of 15.6% [2][7] - Cash, cash equivalents, and marketable securities totaled $28.6 million as of June 30, 2025, down from $41.3 million in December 2024 [8] Business Overview - Sensei Biotherapeutics is focused on developing solnerstotug, a monoclonal antibody targeting the VISTA immune checkpoint in cancer [3][10] - The company aims to demonstrate the efficacy of solnerstotug in patients with cancers resistant to PD-(L)1 treatments, a significant challenge in cancer therapy [4][11] - The ongoing Phase 1/2 clinical trial has enrolled 64 patients, including those with "hot" tumors, which are known to initially respond to immunotherapy but later become resistant [5][10] Clinical Development - Preliminary safety and efficacy data for solnerstotug indicated favorable activity in PD-(L)1 resistant "hot" tumors, with no dose-limiting toxicities reported [6] - Full dose expansion data, including 6-month progression-free survival, are expected by year-end 2025, with a major presentation planned at the ESMO Congress in October 2025 [12] Future Outlook - Management expects current cash resources to fund operations into the second quarter of 2026, emphasizing the importance of ongoing clinical updates and funding strategies [12][13] - The success of solnerstotug is critical for the company's future growth, especially in a competitive immuno-oncology market [11]

PART I FINANCIAL INFORMATION This section covers unaudited financial statements, management's analysis, market risk disclosures, and internal controls [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) Net loss improved to **$11.8 million** in H1 2025, assets decreased, and substantial doubt exists about the company's going concern [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance sheet shows total assets decreased to **$31.8 million** by June 30, 2025, mainly from reduced marketable securities Condensed Consolidated Balance Sheets (in thousands) | | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $12,557 | $9,994 | | Marketable securities | $16,071 | $31,341 | | Total current assets | $29,572 | $41,929 | | Total assets | $31,783 | $45,361 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $3,873 | $5,448 | | Total liabilities | $4,469 | $6,975 | | Total stockholders' equity | $27,314 | $38,386 | | Total liabilities and stockholders' equity | $31,783 | $45,361 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss improved to **$11.8 million** for H1 2025 from **$15.1 million** in 2024, primarily due to reduced operating expenses Statement of Operations Highlights (in thousands, except per share data) | | **Three Months Ended June 30,** | | **Six Months Ended June 30,** | | | :--- | :--- | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | Research and development | $2,533 | $4,584 | $6,258 | $9,501 | | General and administrative | $2,673 | $3,203 | $6,222 | $7,016 | | **Loss from operations** | **($5,206)** | **($7,787)** | **($12,480)** | **($16,517)** | | **Net loss** | **($4,936)** | **($7,142)** | **($11,800)** | **($15,134)** | | Net loss per common share | ($3.91) | ($5.69) | ($9.36) | ($12.07) | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash increased by **$2.56 million** for H1 2025, driven by investing activities offsetting operating cash usage Cash Flow Summary for the Six Months Ended June 30 (in thousands) | | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($13,003) | ($13,408) | | Net cash provided by investing activities | $15,948 | $12,677 | | Net cash used in financing activities | ($382) | ($389) | | **Net increase (decrease) in cash** | **$2,563** | **($1,120)** | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes highlight substantial doubt about going concern, a 1-for-20 reverse stock split, and a November 2024 restructuring - The company has concluded there is **substantial doubt about its ability to continue as a going concern**, as it will not have sufficient cash to fund operations beyond one year from the issuance of the financial statements without additional financing[24](index=24&type=chunk)[25](index=25&type=chunk) - On June 16, 2025, the company effected a **1-for-20 reverse stock split** of its common stock, with all historical share and per-share amounts adjusted to reflect this split[26](index=26&type=chunk) - In November 2024, the company initiated a **restructuring** to focus resources on its lead candidate, solnerstotug, involving closing a research site and reducing its workforce by approximately **46%**[76](index=76&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses solnerstotug, restructuring, decreased net loss, and critical liquidity concerns with going concern doubt [Overview](index=23&type=section&id=Overview) Overview details the company's clinical-stage biotech focus on solnerstotug and the impact of its November 2024 restructuring - The company is a clinical-stage biotechnology firm focused on its TMAb™ (Tumor Microenvironment Activated Biologics) platform to develop cancer therapeutics[81](index=81&type=chunk) - The lead product candidate, **solnerstotug**, is in a Phase 1/2 clinical trial, with updated data expected by the end of 2025 and Phase 2 studies planned for 2026, contingent on additional capital[82](index=82&type=chunk) - A November 2024 **restructuring** decreased operating expenses and focused resources on solnerstotug, involving a **46% workforce reduction** and pausing preclinical candidates[84](index=84&type=chunk) [Results of Operations](index=28&type=section&id=Results%20of%20Operations) Operating expenses significantly decreased in 2025 compared to 2024 for both periods, primarily due to the November 2024 restructuring Comparison of Operating Expenses (in thousands) | | **Three Months Ended June 30,** | | **Six Months Ended June 30,** | | | :--- | :--- | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | Research and development | $2,533 | $4,584 | $6,258 | $9,501 | | General and administrative | $2,673 | $3,203 | $6,222 | $7,016 | | **Total operating expenses** | **$5,206** | **$7,787** | **$12,480** | **$16,517** | - The decrease in operating expenses for both the three and six-month periods of 2025 compared to 2024 was primarily driven by lower personnel costs (including stock-based compensation), reduced facilities and equipment costs, and lower manufacturing and research fees, all resulting from the November 2024 restructuring[102](index=102&type=chunk)[103](index=103&type=chunk)[106](index=106&type=chunk)[107](index=107&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity is constrained with **$28.6 million** cash and **$273.9 million** accumulated deficit, raising substantial doubt about funding operations beyond Q2 2026 - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities of **$28.6 million** and an accumulated deficit of **$273.9 million**[109](index=109&type=chunk) - Based on current operating plans, the company expects its existing cash to fund operations and capital expenditures only into the **second quarter of 2026**[122](index=122&type=chunk) - Management has concluded that there is **substantial doubt about the company's ability to continue as a going concern** and will require additional financing to support its operations[122](index=122&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=37&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company, as a smaller reporting entity, is exempt from providing quantitative and qualitative disclosures about market risk - As a smaller reporting company, the company is not required to provide the information otherwise required under this item[136](index=136&type=chunk) [Item 4. Controls and Procedures](index=37&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting during the quarter - Management, including the principal executive officer and principal financial officer, evaluated the effectiveness of disclosure controls and procedures and concluded they were **effective** at a reasonable assurance level as of June 30, 2025[139](index=139&type=chunk) - No material changes in internal control over financial reporting occurred during the three months ended June 30, 2025[140](index=140&type=chunk) PART II OTHER INFORMATION This section covers legal proceedings, significant risk factors, unregistered equity sales, and other miscellaneous information [Item 1. Legal Proceedings](index=38&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings - The company is not currently a party to any material legal proceedings[143](index=143&type=chunk) [Item 1A. Risk Factors](index=38&type=section&id=Item%201A.%20Risk%20Factors) Key risks include financial instability, funding needs, early-stage product development, third-party reliance, and regulatory hurdles [Risks Related to Our Financial Position](index=40&type=section&id=Risks%20Related%20to%20Our%20Financial%20Position) Financial risks include urgent funding needs, a history of substantial losses, and material uncertainty about the company's going concern ability - The company requires **substantial additional funding** to continue operations; failure to obtain capital could force it to delay, reduce, or terminate development and commercialization efforts[150](index=150&type=chunk) - The company has a history of significant losses, with a net loss of **$11.8 million** for the first six months of 2025 and an accumulated deficit of **$273.9 million** as of June 30, 2025[162](index=162&type=chunk) - There is **substantial doubt about the company's ability to continue as a going concern**, as its current cash, cash equivalents, and marketable securities are only expected to fund operations into the second quarter of 2026[170](index=170&type=chunk) [Risks Related to the Development of our Product Candidates](index=46&type=section&id=Risks%20Related%20to%20the%20Development%20of%20our%20Product%20Candidates) Product development risks include early-stage candidates, high dependence on solnerstotug, lengthy regulatory processes, and potential changes in interim data - The company's development efforts are in early stages, and its business is highly dependent on the success of its product candidates, particularly **solnerstotug**, which requires significant additional development and regulatory approval[176](index=176&type=chunk)[190](index=190&type=chunk) - The regulatory approval process for product candidates is lengthy, expensive, and unpredictable, with no guarantee of success[183](index=183&type=chunk) - Interim and preliminary data from clinical trials may change as more patient data becomes available, and positive early results are not predictive of final outcomes[200](index=200&type=chunk)[202](index=202&type=chunk) [Risks Related to our Dependence on Third Parties](index=61&type=section&id=Risks%20Related%20to%20our%20Dependence%20on%20Third%20Parties) Risks arise from reliance on third-party CROs for clinical trials, CMOs for production, and supply agreements for combination therapies - The company relies on third-party Contract Research Organizations (CROs) to conduct its clinical trials, and poor performance by these CROs could delay or prevent regulatory approval[222](index=222&type=chunk)[223](index=223&type=chunk) - The company depends on Contract Manufacturing Organizations (CMOs) for the production of its product candidates, including solnerstotug, which creates risks related to supply sufficiency, cost, and quality control[236](index=236&type=chunk) - The clinical trial of solnerstotug in combination with cemiplimab is dependent on a supply agreement with Regeneron, and any disruption could delay development[232](index=232&type=chunk)[234](index=234&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=117&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - There were no recent sales of unregistered equity securities[407](index=407&type=chunk) [Item 3. Defaults Upon Senior Securities](index=117&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None[410](index=410&type=chunk) [Item 4. Mine Safety Disclosures](index=117&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[411](index=411&type=chunk) [Item 5. Other Information](index=117&type=section&id=Item%205.%20Other%20Information) No officers or directors adopted, modified, or terminated a Rule 10b5-1 trading plan during the quarter ended June 30, 2025 - No officers or directors adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the fiscal quarter[412](index=412&type=chunk) [Item 6. Exhibits](index=117&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including the company's articles of incorporation, bylaws, and certifications from the Principal Executive Officer and Principal Financial Officer as required by the Sarbanes-Oxley Act - The exhibits filed with the report include certifications from the Principal Executive Officer and Principal Financial Officer pursuant to Sarbanes-Oxley Act Sections 302 and 906[415](index=415&type=chunk)

[Corporate and Clinical Program Highlights](index=1&type=section&id=Corporate%20and%20Clinical%20Program%20Highlights) Sensei Biotherapeutics updated on solnerstotug's Phase 1/2 data expected by year-end 2025 and corporate events [CEO Commentary and Strategy](index=1&type=section&id=CEO%20Commentary%20and%20Strategy) The CEO outlined solnerstotug's strategic shift, emphasizing its safety profile and potential in the PD-(L)1 resistant market - Solnerstotug, in combination with cemiplimab, has demonstrated a favorable safety profile with no significant additional toxicity compared to PD-(L)1 monotherapy[3](index=3&type=chunk) - The company envisions multiple Phase 2 studies for solnerstotug in PD-(L)1 resistant tumor types to target high-value segments of the **~$50 billion** PD-(L)1 market[3](index=3&type=chunk) - The final Phase 2 strategy will be strongly influenced by the full dose expansion dataset planned for presentation later in 2025[3](index=3&type=chunk) [Solnerstotug Clinical Program Update](index=1&type=section&id=Solnerstotug%20Clinical%20Program%20Update) The Phase 1/2 solnerstotug trial completed enrollment with 64 patients; full data expected by year-end 2025 - Full dose expansion data, including 6-month progression-free survival (PFS), from the Phase 1/2 study is expected by year-end 2025[5](index=5&type=chunk) Phase 1/2 Dose Expansion Cohort Enrollment | Arm | Patient Group | Number of Patients | | :--- | :--- | :--- | | Monotherapy | "Cold" MSS CRC | 10 | | Combination (with cemiplimab) | "Cold" MSS CRC | 10 | | Combination (with cemiplimab) | "Hot" Tumors (41/44 PD-(L)1 resistant) | 44 | | **Total** | | **64** | [Other Corporate Updates](index=2&type=section&id=Other%20Corporate%20Updates) Sensei announced favorable clinical data, an ESMO presentation, and regained Nasdaq compliance post-split - Clinical data from the dose expansion cohort will be presented at the European Society for Medical Oncology (ESMO) Congress in October 2025[11](index=11&type=chunk) - The company regained Nasdaq compliance after executing a 1-for-20 reverse stock split of its common stock, effective June 16th[11](index=11&type=chunk) - On March 27th, Sensei announced favorable preliminary clinical data from the dose expansion stage, demonstrating positive activity in patients with PD-(L)1 resistant "hot" tumors[11](index=11&type=chunk) [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) Sensei Biotherapeutics reported **$28.6 million** cash for Q2 2025, with reduced expenses and a **$4.9 million** net loss [Financial Performance Summary](index=2&type=section&id=Financial%20Performance%20Summary) Cash position was **$28.6 million** as of June 30, 2025, with reduced expenses and a **$4.9 million** net loss - Cash, cash equivalents, and marketable securities totaled **$28.6 million** as of June 30, 2025, which is expected to fund operations into the second quarter of 2026[7](index=7&type=chunk) Q2 2025 vs. Q2 2024 Operating Results (in millions) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | R&D Expenses | $2.5 million | $4.6 million | | G&A Expenses | $2.7 million | $3.2 million | | Net Loss | $4.9 million | $7.1 million | [Condensed Financial Statements](index=3&type=section&id=Condensed%20Financial%20Statements) Unaudited Q2 2025 statements show **$5.2 million** operating expenses, **$4.9 million** net loss, and **$31.8 million** total assets Condensed Statements of Operations (Unaudited, in thousands) | | Three Months Ended June 30, | | | :--- | :--- | :--- | | | **2025** | **2024** | | Research and development | $2,533 | $4,584 | | General and administrative | $2,673 | $3,203 | | **Total operating expenses** | **$5,206** | **$7,787** | | **Net loss** | **$(4,936)** | **$(7,142)** | | Net loss per share, basic and diluted | $(3.91) | $(5.69) | Selected Condensed Balance Sheet Data (Unaudited, in thousands) | | **June 30, 2025** | **December 31, 2024** | | :--- | :--- | :--- | | Cash and cash equivalents | $12,557 | $9,994 | | Marketable securities | $16,071 | $31,341 | | **Total assets** | **$31,783** | **$45,361** | | Total stockholders' equity | $27,314 | $38,386 | [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) This section outlines forward-looking statements on product development, clinical trials, and financial runway, subject to risks - Statements regarding product development, clinical trial timing for solnerstotug, and the company's cash runway are forward-looking and based on current expectations[15](index=15&type=chunk) - Key risks include the potential for product candidates not to be successfully developed or commercialized, delays in clinical trials, and prior results not being replicated in future studies[16](index=16&type=chunk) - The company refers to its Quarterly Report on Form 10-Q and other SEC filings for a more detailed description of risks and uncertainties[16](index=16&type=chunk)

Core Viewpoint - Sensei Biotherapeutics is transitioning from early response-focused readouts to longer-term efficacy signals in its Phase 1/2 study of solnerstotug, which shows a favorable safety profile and potential for better patient adherence and outcomes [2][3] Clinical Program Highlights - Full data for the Phase 1/2 dose expansion cohort is expected by year-end 2025, with enrollment complete at 64 patients [6] - The ongoing trial evaluates solnerstotug as a monotherapy and in combination with cemiplimab in patients with advanced solid tumors [3] - Preliminary clinical data indicates favorable activity in PD-(L)1 resistant "hot" tumors, with solnerstotug well tolerated and no dose-limiting toxicities reported [6] Corporate Updates - Sensei's cash position was $28.6 million as of June 30, 2025, down from $41.3 million at the end of 2024, with expectations to fund operations into Q2 2026 [8] - Research and Development expenses decreased to $2.5 million in Q2 2025 from $4.6 million in Q2 2024, attributed to lower personnel and facility costs [9] - General and Administrative expenses also decreased to $2.7 million in Q2 2025 from $3.2 million in Q2 2024, primarily due to lower personnel costs [10] Financial Results - The net loss for Q2 2025 was $4.9 million, an improvement from a net loss of $7.1 million in Q2 2024 [10] - Total operating expenses for Q2 2025 were $5.2 million, down from $7.8 million in Q2 2024 [13]

Core Insights - The broader stock market experienced significant losses due to trade policy changes and negative economic data, while select health technology stocks, including 4D Molecular Therapeutics, Sensei Biotherapeutics, and Alphatec Holdings, saw substantial gains averaging around 37% [1] Group 1: 4D Molecular Therapeutics - Shares of 4D Molecular Therapeutics surged over 42% to close at $6.42 following the release of promising clinical data for its gene therapy candidate, 4D-150, targeting diabetic macular edema and wet age-related macular degeneration [2] - The therapy showed strong, dose-dependent results, with a reported 78% reduction in treatment burden at the Phase 3 dose compared to standard aflibercept dosing, along with sustained visual improvements and no reported inflammation [4] - The European Medicines Agency endorsed the company's plan to seek approval based on a single Phase 3 trial, aligning with earlier FDA guidance [5] Group 2: Sensei Biotherapeutics - Sensei Biotherapeutics emerged as a top gainer despite no major company-specific news, likely due to increased speculative interest in its immuno-oncology pipeline and anticipation of upcoming trial data [6] - The stock rose 38% to close at $10.32, following the announcement that Sensei will present clinical data from its Phase 1/2 trial of its lead candidate at the European Society for Medical Oncology Congress on October 17 [7] Group 3: Alphatec Holdings - Alphatec Holdings' stock jumped 30% to close at $13.77 after the company raised its full-year 2025 revenue outlook to $742 million, driven by strong demand for its surgical platforms and EOS imaging technologies [9] - The company reported second-quarter 2025 revenue of $185.5 million, reflecting a 28% year-over-year increase, although it also reported a widened net loss of $41.1 million, or $0.27 per share [11] - Despite remaining unprofitable, investor confidence appears to be increasing in Alphatec's commercial execution and long-term growth prospects [12]

Core Insights - Sensei Biotherapeutics, Inc. announced the presentation of clinical data from the Phase 1/2 trial of solnerstotug, both alone and in combination with Libtayo, at the ESMO Congress 2025 in Berlin [1] Company Overview - Sensei Biotherapeutics is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [2] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target immunosuppressive signals in the tumor microenvironment [2] - Solnerstotug is the lead product candidate, designed to block the VISTA checkpoint selectively in low pH tumor environments, enhancing T cell activation [2]

Core Viewpoint - Sensei Biotherapeutics, Inc. is implementing a 1-for-20 reverse stock split to comply with Nasdaq Capital Market's minimum bid price requirement, effective June 16, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of issued and outstanding shares from approximately 25.2 million to about 1.3 million [3]. - The authorized shares will decrease from 250 million to 12.5 million [3]. - Fractional shares will not be issued; instead, stockholders entitled to fractional shares will receive a cash payment [4]. Group 2: Trading Information - The common stock will begin trading on a split-adjusted basis on June 17, 2025, under the existing trading symbol "SNSE" [2]. - Equiniti Trust Company, LLC will act as the exchange agent and transfer agent for the reverse stock split [5]. Group 3: Company Overview - Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer patients through its TMAb™ platform [6]. - The lead product candidate, solnerstotug, is designed to block the VISTA checkpoint selectively within the tumor microenvironment [6].